Schedule 13D ownership disclosure

EDESA BIOTECH INC

Common Shares, without par value · CUSIP: 27966L306

Event date: 2025-02-12

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Velan Capital Master Fund LPReported CIK 0001964356

    Shares: 427,926.00 · Class: 6.2%

  • Velan Horizon Fund LP

    Shares: 15,625.00 · Class: 0.2%

  • Velan Capital Opportunity Fund II LLC

    Shares: 250,000.00 · Class: 3.6%

  • Velan Horizon GP LLC

    Shares: 15,625.00 · Class: 0.2%

  • Velan Capital Holdings LLCReported CIK 0001964353

    Shares: 677,926.00 · Class: 9.8%

  • Velan Capital Investment Management LPReported CIK 0001848809

    Shares: 693,551.00 · Class: 9.99%

  • Velan Capital Management LLCReported CIK 0001964355

    Shares: 693,551.00 · Class: 9.99%

  • Morgan AdamReported CIK 0001964335

    Shares: 693,551.00 · Class: 9.99%

  • VENKATARAMAN BALAJIReported CIK 0001114916

    Shares: 693,551.00 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-000528
Form type
SCHEDULE 13D
Filer
Edesa Biotech, Inc.
CIK
CIK 1540159
Filed
Feb 18, 2025
Reporting period
Feb 12, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub